Spots Global Cancer Trial Database for indoximod
Every month we try and update this database with for indoximod cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer | NCT01560923 | Metastatic Pros... | Indoximod Sipuleucel-T Placebo | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | NCT05106296 | Ependymoma Medulloblastoma Glioblastoma Primary Brain T... | Ibrutinib Indoximod Cyclophosphamid... Etoposide | 12 Years - 25 Years | Augusta University | |
| Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | NCT02073123 | Metastatic Mela... Stage III Melan... Stage IV Melano... | Indoximod Ipilimumab Nivolumab Pembrolizumab | 18 Years - | Lumos Pharma | |
| Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | NCT02052648 | Glioblastoma Mu... Glioma Gliosarcoma Malignant Brain... | Indoximod Temozolomide Bevacizumab Stereotactic Ra... | 16 Years - | Lumos Pharma | |
| Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | NCT05106296 | Ependymoma Medulloblastoma Glioblastoma Primary Brain T... | Ibrutinib Indoximod Cyclophosphamid... Etoposide | 12 Years - 25 Years | Augusta University | |
| Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | NCT02052648 | Glioblastoma Mu... Glioma Gliosarcoma Malignant Brain... | Indoximod Temozolomide Bevacizumab Stereotactic Ra... | 16 Years - | Lumos Pharma | |
| A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma | NCT03301636 | Melanoma | Pembrolizumab Nivolumab Indoximod | 18 Years - | Lumos Pharma | |
| A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma | NCT03301636 | Melanoma | Pembrolizumab Nivolumab Indoximod | 18 Years - | Lumos Pharma | |
| Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | NCT02073123 | Metastatic Mela... Stage III Melan... Stage IV Melano... | Indoximod Ipilimumab Nivolumab Pembrolizumab | 18 Years - | Lumos Pharma | |
| Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | NCT02077881 | Metastatic Panc... Metastatic Panc... | Nab-Paclitaxel Gemcitabine Indoximod | 18 Years - | Lumos Pharma | |
| Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | NCT02502708 | Glioblastoma Mu... Glioma Gliosarcoma Malignant Brain... Ependymoma Medulloblastoma Diffuse Intrins... Primary CNS Tum... | Indoximod Temozolomide Conformal Radia... Cyclophosphamid... Etoposide | 3 Years - 21 Years | Lumos Pharma | |
| Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | NCT02460367 | Non-small Cell ... Progression of ... Non-small Cell ... | Docetaxel Tergenpumatucel... Indoximod | 18 Years - | Lumos Pharma | |
| Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | NCT02077881 | Metastatic Panc... Metastatic Panc... | Nab-Paclitaxel Gemcitabine Indoximod | 18 Years - | Lumos Pharma | |
| Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | NCT02460367 | Non-small Cell ... Progression of ... Non-small Cell ... | Docetaxel Tergenpumatucel... Indoximod | 18 Years - | Lumos Pharma | |
| Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | NCT02460367 | Non-small Cell ... Progression of ... Non-small Cell ... | Docetaxel Tergenpumatucel... Indoximod | 18 Years - | Lumos Pharma | |
| Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | NCT02502708 | Glioblastoma Mu... Glioma Gliosarcoma Malignant Brain... Ependymoma Medulloblastoma Diffuse Intrins... Primary CNS Tum... | Indoximod Temozolomide Conformal Radia... Cyclophosphamid... Etoposide | 3 Years - 21 Years | Lumos Pharma |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
